Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Payables: 2009-2024

Historic Payables for Gyre Therapeutics (GYRE) over the last 15 years, with Dec 2024 value amounting to $108,000.

  • Gyre Therapeutics' Payables rose 83.50% to $556,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $857,000, marking a year-over-year decrease of 31.93%. This contributed to the annual value of $108,000 for FY2024, which is 69.58% down from last year.
  • As of FY2024, Gyre Therapeutics' Payables stood at $108,000, which was down 69.58% from $355,000 recorded in FY2023.
  • Gyre Therapeutics' 5-year Payables high stood at $7.7 million for FY2022, and its period low was $108,000 during FY2024.
  • For the 3-year period, Gyre Therapeutics' Payables averaged around $2.7 million, with its median value being $355,000 (2023).
  • As far as peak fluctuations go, Gyre Therapeutics' Payables rose by 19.64% in 2022, and later slumped by 95.38% in 2023.
  • Gyre Therapeutics' Payables (Yearly) stood at $5.9 million in 2020, then climbed by 8.23% to $6.4 million in 2021, then climbed by 19.64% to $7.7 million in 2022, then plummeted by 95.38% to $355,000 in 2023, then tumbled by 69.58% to $108,000 in 2024.